Which account would you like to be logged in as?

Forgot Password?

Sign Up!

Visa/MasterCard and Discover Users
Flip your credit card over and look at the signature box. You should see either the entire 16-digit credit card number or just the last four digits followed by a special 3-digit code. The 3-digit code is your Card Security Code.

American Express Credit Card Users
Look for the 4-digit code printed on the front of your card just above and to the right of your main credit card number. The 4-digit code is your card Identification Number (CID).

What is a discount code?
Generic discount code text needs to go here

Newsletter
jul 6
2011
Release date

Advances in the Management of Ovarian Cancer: Highlights from the 2011 ASCO Annual Meeting

Gynecologic Malignancies

MEDIA: Newsletter

Estimated time to complete activity: 1.0 hour | Release date: Wednesday, July 06, 2011 | Expiration date: Thursday, July 05, 2012

INTRODUCTION

The 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 3-7, brought together over 30,000 clinicians and healthcare professionals. This newsletter highlights key data and information presented on ovarian cancer, including discussions on optimizing treatment and improving patient outcomes.

FEATURED CONTENT

Phase III Studies of Bevacizumab for the Treatment of Advanced Epithelial Ovarian Cancer
Combination Regimens With Pegylated Liposomal Doxorubicin
Phase II Trials of Targeted Agents for Epithelial Ovarian Cancer
Evaluating Screening Modalities in Epithelial Ovarian Cancer
Molecular Taxonomy of Epithelial Ovarian Cancer

EDITORS


Angeles Alvarez Secord, MD

Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Judith K. Wolf, MD

Section Chief of Surgery
Banner MD Anderson Cancer Center
Phoenix, Arizona

TARGET AUDIENCE

The intended audience for this initiative includes gynecologic oncologists, medical oncologists, surgical oncologists, and oncology specialty pharmacists caring for patients with ovarian cancer.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to:

  • Discuss updated efficacy and toxicity data for clinically available treatment options for patients with ovarian cancer
  • Incorporate clinical data describing new therapeutic agents or strategies into clinical practice to improve response and survival rates for patients with ovarian cancer
  • Correlate toxicity and tolerability data for therapeutic agents used to treat ovarian cancer with their impact on patient quality of life
  • Describe the proposed mechanisms of action of new and emerging therapeutic agents in development for the management of patients with ovarian cancer
  • Explain the implications of genetic analysis and biomarkers on treatment selection and response as they currently relate to patients with ovarian cancer

PHYSICIAN CONTINUING EDUCATION

Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

ACPE Logo Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-11-022-H01-P).

Type of activity: Knowledge-based

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this activity. During the period Wednesday, July 06, 2011 through Thursday, July 05, 2012, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

CME/CE CREDIT

Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.

POLICY ON DISCLOSURE

It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME/CE activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.

The Following Faculty Members Have Declared Relevant Financial Relationships

Angeles Alvarez Secord, MD Grants/Research Support Abraxis BioScience
Bristol-Myers Squibb
Eisai Inc.
GlaxoSmithKline
Morphotek Inc.
Precision Therapeutics, Inc.
sanofi-aventis
Consultant Fees Abraxis BioScience
Boehringer Ingelheim
Pfizer Inc
Precision Therapeutics, Inc.
Honorarium Lilly USA, LLC
Speakers’ Bureau Lilly USA, LLC
Judith K. Wolf, MD No relevant financial relationships to disclose

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.

ACKNOWLEDGEMENT

The editors wish to thank Java Solis, MS, for assistance in writing this document.

DISCLOSURE OF OFF-LABEL USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from the following: Genentech

CME/CE INQUIRIES

For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

Yes, I have read the information above and am interested in participating.